

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number  
**WO 2005/077420 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 47/38**,  
9/14, 31/18, A61P 13/08

(21) International Application Number:  
PCT/KR2005/000422

(22) International Filing Date: 16 February 2005 (16.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10-2004-0010384  
17 February 2004 (17.02.2004) KR

(71) Applicant (for all designated States except US): **HANMI  
PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-  
myeon, Hwaseong-gun, Kyungki-do 445-910 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WOO, Jong Soo**  
[KR/KR]; Daewolmaeul 821-105, #914, Jeongja-dong,

Jangan-gu, Suwon-si, Kyungki-do 440-300 (KR).  
**CHANG, Hee Chul** [KR/KR]; 302-ho, #290-4, Go-  
saik-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-360  
(KR).


(74) Agents: **JANG, Seongku** et al.; 19th Fl., KEC Building,  
#275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: COMPOSITION FOR ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE AND CONTROLLED  
RELEASE GRANULE FORMULATION COMPRISING SAME



(57) Abstract: A composition for oral administration of tamsulosin hydrochloride and a controlled release granule formulation comprising the same exhibited excellent stability and sustained release characteristics of tamsulosin hydrochloride regardless of pH changes for an extended period of time.



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*